Werewolf Therapeutics Inc
werewolftx.comWhat Do They Do?
Develops conditionally activated immune therapies for cancer and other immune-mediated conditions, including cytokine drugs and T-cell-engaging drugs for patients.
10-K for FY2025, filed Mar 27, 2026
Who Are Their Customers?
Jazz Pharmaceuticals Ireland Limited received worldwide development and commercialization rights to JZP898 under a global collaboration and license agreement.
10-K for FY2025, filed Mar 27, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 31, 2026
$3.7MView ↗
- ▲ Now profitable
- vs −$18M in Q2 FY2025
-
Aug 21, 2026
Agreed to merge with Ambros Therapeutics
The proposed all-stock merger would make Ambros a subsidiary, with the combined company focused on Ambros’s neridronate program.
Sources
8-K, filed Aug 21, 2026
On August 21, 2026, Werewolf Therapeutics, Inc., a Delaware corporation (“Werewolf”), entered into an Agreement and Plan of Merger (the…View ↗
-
Aug 20, 2026
Sold preclinical platform assets to EMD Serono
The sale covered the preclinical INDUCER platform and parts of INDUKINE, while Werewolf retained rights needed for WTX-124 and WTX-330.
Sources
8-K, filed Aug 20, 2026
On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase…View ↗
Adds immune-cell engagers
The older report focused on INDUKINE cytokine molecules; the latest also describes INDUCER immune-cell engagers, including T-cell engagers, built with the PREDATOR platform.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 27, 2026We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system…View ↗
We are also utilizing this PREDATOR platform know-how and expertise to develop conditionally activated immune cell engagers. Immune cell…View ↗
Who Do They Compete With?
Competes with Anaveon, Anwita Biosciences, Ascendis Pharma, Asher Biotherapeutics, Aulos Bioscience, BioNTech, Cue Biopharma, DEKA Biosciences, Merck &, Medicenna Therapeutics, F. Hoffmann-La Roche, Synthekine, Xilio Therapeutics, Sanofi, DragonFly Therapeutics, Juno Therapeutics, Bristol-Myers Squibb, OncoSec Medical, PDS Biotechnology, and Philogen
10-K for FY2025, filed Mar 27, 2026Our lead product candidate, WTX-124, if approved, may face competition from other IL-2 based cancer therapies. Proleukin (aldesleukin) has…View ↗
Loading...
